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ABSTRACT
 
Innovations in medical device technology have greatly expanded
the range of therapeutic options available to physicians and their
patients. The understanding of treatment effects from the
patient’s perspective is an essential component of a comprehen-
sive assessment of any new therapy, including medical devices.
The term “patient-reported outcomes” (PROs) has been growing
in use to refer to a cluster of variables such as health-related qual-
ity of life, symptoms, physical functioning, psychological well-
being, treatment satisfaction, and treatment preferences. As in
drug trials, the use of PROs in device evaluation has several
methodological challenges, ranging from general concerns about
interpretation, to more speciﬁc issues related to study design and
regulatory approval (use of PROs as primary end points, incor-
poration in labeling, and product promotion). Successful
approaches for integrating PROs into device evaluation trials
include the careful selection of appropriate, interpretable PRO
end points, accounting for possible confounding factors, and the
use of alternatives to placebo-controlled trial designs, such as sin-
gle-arm pre–post, observational, and registry studies, when the
use of placebo control groups is not feasible. This article dis-
cusses the potential value and difﬁculties in measuring PROs in
device studies.
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Introduction
 
Patient perception of disease and treatment is integral
to the clinical decision-making process. The patient is
an essential source of information to accurately and
appropriately diagnose disease, assess and monitor
disease activity, select and adjust treatment, and eval-
uate the outcomes of care. Patient-reported outcomes
(PROs) refer to a set of variables that provide infor-
mation on the effect of therapy or intervention from
the perspective of the person undergoing that therapy
[1]. Symptoms, physical functioning, psychological
well-being, treatment satisfaction, and treatment pref-
erences are all examples of PROs [2]. The perspective
of the patient’s personal caregiver, including percep-
tion of patient functioning or caregiver burden (impor-
tant outcomes in conditions such as Alzheimer’s
disease), is sometimes considered part of this outcome
group.
New devices are emerging that offer primary pre-
ventive and ﬁrst-line therapeutic alternatives with
health outcomes that rival those of drug therapies [3].
With advancements in technology, devices have
expanded beyond the traditional implantables to
include a wider range of both diagnostic and therapeu-
tic products. As in the case of pharmaceutical trials,
the use of PROs in device trials is associated with prac-
tical, methodological, and regulatory challenges that
need to be addressed to maximize PRO scientiﬁc valid-
ity and enhance their utility as key outcomes in device
evaluation. The purpose of this article is to discuss the
potential value and difﬁculties in measuring PROs in
device studies.
 
The Value of PROs in Device Evaluation
 
Several key factors have led to the increase in interest
for PRO data in evaluating the performance of all
medical products, including medical devices. First, the
upsurge in patient and consumer empowerment and
their involvement in health-care decision-making
requires that the patient’s perception of treatment be
understood and communicated. As individuals and
through patient advocacy groups, patients increasingly
are voicing their concerns about treatment options and
their desire to be involved in decisions regarding their
own care. Advertising and information access through
the worldwide web have led to a health-care consumer
society that is more informed and more demanding than
ever before. Evaluating outcomes from the patient’s
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perspective is an important step in addressing the infor-
mation requirements of these important decision-
makers. A second factor driving the need for PRO data
is the increasing variety of health-care options. As deci-
sion-makers (providers, patients, and payers) choose a
drug or device or, with increasing frequency, between
drugs and devices, they need to understand their relative
risks and beneﬁts. The rising health-care costs have led
to pressure in the public and private health-care sectors
to reduce and/or justify health-care expenditures [4].
Demonstrating the effect of a new and potentially
expensive treatment on PROs is an important dimen-
sion of demonstrating product value. Increasingly, par-
ticularly in the UK and Canada, this information takes
the form of cost per quality-adjusted life-year, that is,
per year of life adjusted for the quality of that year [5].
Quality is typically based on a PRO.
Patient-reported outcomes can provide important
information on the advantages and disadvantages of
therapeutic options not otherwise captured through
non-PRO clinical end points. In many cases, particu-
larly terminal illness, PROs such as health-related
quality of life are usually the determining factors in
treatment selection. Devices intended for terminal con-
ditions such as heart failure represent one of many
promising areas of value for PRO research. Heart fail-
ure, an illness with considerable morbidity and mor-
tality, has limited treatment options. For such
conditions, device solutions are not intended to be cur-
ative, but rather, designed to reduce patient morbidity.
The challenge in assessing such technologies lies in
the proper determination of an acceptable trade-off
between an improved health-related quality of life and
an increased risk of adverse events.
The use of PROs to understand the magnitude of
adverse events from the patient’s perspective or the
effect of these events on patient functioning and well-
being, in addition to the health beneﬁt of the treat-
ment, should  not  be  overlooked,  particularly  when
a new device offers a different adverse event proﬁle.
The Multicenter Automatic Deﬁbrillator Implantation
Trial II, for example, showed reduced mortality asso-
ciated with an implantable cardiac deﬁbrillator (ICD)
relative to conventional medical therapy, but the ICD
arm also had a higher rate of hospitalizations because
of heart failure and longer hospital lengths of stay [6].
Moreover, depression, anxiety, and “phantom shock”
syndrome attributed to anxiety of ICD shocks have
been reported in the clinical community [7]. Use of
PROs that can translate the increased rate of hospital-
izations and psychiatric events into effects on overall
patient well-being would enhance the understanding
of treatment outcomes beyond mortality.
In addition to terminal illness, PROs can also be a
primary outcome measure in assessments of “lifestyle
devices,” the description given to the host of new
devices that focus on lifestyle concerns such as sexual
functioning or aging [8]. The main purpose of these
devices is to improve various aspects of health-related
quality of life, that is, the ability of a person to realize
their physical, social, and emotional potential, among
individuals who may not necessarily have a severe
health problem. An example of such a device is Ther-
mage, a wand-and-tip device that contracts the under-
lying skin to erase wrinkles and tighten sagging skin
[8].
 
PRO in Device and Drug 
Evaluation: Distinctions
 
A review of differences between the device and drug
evaluation process forms the foundation for under-
standing the challenges associated with the use of
PROs in the device evaluation process. The most
important difference between drug and device devel-
opment and evaluation is in the regulatory approval
process itself, that is, the process through which the
two classes of treatment are reviewed before their
introduction into the marketplace. Brieﬂy, drug
approval process begins with preliminary/preclinical
testing of a new product in animals, followed by a ﬁl-
ing of an Investigational New Drug Application (IND).
The IND is followed by phase I trials, testing the
metabolism and safety of the new drug in a small
number of healthy volunteers, phase II studies, gener-
ally dose-ranging studies to evaluate safety and efﬁcacy
in the patient population, and ﬁnally larger phase III
pivotal trials evaluating safety and efﬁcacy in a larger,
more heterogeneous patient population. With this
process successfully completed, the manufacturer ﬁles
a New Drug Application requesting approval to put
the drug on the market with the appropriate label
describing the characteristics of the product for the
prescriber and upon which to base marketing materi-
als. Drug development usually involves at least two
well-controlled pivotal phase III trials before approval.
Postapproval, late stage studies (phase IV trials,
safety registries, effectiveness trials) are often con-
ducted to evaluate the effect of the product in various
subpopulations and at varying doses or indications,
and its long-term beneﬁt and risk proﬁle. Throughout
this process, PRO data are gathered to understand,
and ultimately communicate, treatment efﬁcacy, safety,
and value from the patient’s perspective. The longitu-
dinal, multiphase drug development and approval
process offers manufacturers an opportunity to evalu-
ate PRO measurement options and test treatment
effects under various scenarios, leading to a portfolio
of data for understanding the effect of treatment from
this perspective.
Medical devices are generally deﬁned as instru-
ments intended: 1) for use in the diagnosis, cure,
mitigation, treatment, or prevention of disease or con-
dition; or 2) to affect the structure or any function of
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the body which does not achieve its intended use
through chemical action. Approaches to clinical eval-
uation and approval of medical devices must take into
consideration the therapeutic use for which the device
is intended, the technological characteristics of the
device, and the level of potential risk inherent to the
device. The evaluation of medical devices has under-
gone considerable evolution over the last couple of
decades. Use of rigorous evaluation standards, includ-
ing randomized trials, well-characterized controls, and
prospectively deﬁned statistical hypotheses that are the
established paradigm of drug evaluation are increas-
ingly being applied to a wider array of medical devices,
including traditionally low-risk technologies.
The ﬁrst step in the evaluation process is to com-
pare the device with existing, marketed (“predicate”)
devices in terms of design, materials, and use. If the
new device is shown to be “substantially equivalent”
to the predicate device through this (510(k)) process, it
is assigned to the same regulatory class. The advan-
tage, of course, is speed to market; the disadvantage is
the limited opportunity to evaluate and communicate
PRO outcomes of treatment. It should be noted that
PROs for therapeutic devices generally are more
important than PROs for diagnostic products in the
510(k) process. If there is no predicate device, clinical
data (and manufacturing methods) must be reviewed
by the Food and Drug Administration (FDA) to deter-
mine if the device is safe and effective for its intended
use before it can proceed to the marketplace.
The medical device classiﬁcation system is the foun-
dation of the FDA medical device approval and clear-
ance process and does not have an analogous system in
drug evaluation. Unlike pharmaceuticals, all medical
devices are classiﬁed by their level of clinical risk, with
class I representing a minimal risk device, class II inter-
mediate risk, and class III signiﬁcant risk, in order of
the likelihood of associated adverse effects and con-
comitant need for regulatory scrutiny. For devices that
represent a signiﬁcant clinical risk (class III), a manu-
facturer must provide the FDA with valid scientiﬁc evi-
dence that a device is safe and effective when used as
intended as a condition for marketing approval. Exam-
ples of class III cardiovascular devices include most
implantable devices, such as intracoronary stents,
atrial pacemakers, and left ventricular assist devices.
Other devices, including cardiac diagnostic equipment
such as computerized electrocardiographic devices, are
considered to be intermediate risk (class II) and require
the determination of substantial equivalence to an
approved device to be cleared for marketing. Class I
devices are considered minimal risk and are exempt
from most regulatory requirements [9]. Device manu-
facturers also conduct postmarketing surveillance, a
requirement of the Safe Medical Devices Act of 1990.
Differences in the drug and device regulations for
IND and Pre-Market Approval (PMA) applications for
new drugs and devices, respectively, also lead to dif-
ferences in both the opportunity to gather PRO data
and the context within which these data are captured.
Because testing of metabolism and dose-ranging is
not necessary for devices, phase I and II trials are
often combined into one trial. Also, PMA regulations
require data for “reasonable assurance” of effective-
ness and safety claims made by the manufacturer
[10,11], and therefore empiric evidence of PRO out-
comes of treatment may not be part of the PMA
package [10]. Finally, some phase III pivotal device
studies—including those to support class III devices—
can be prospective, unblinded trials designed to show
the device is safe and effective as labeled [9].
 
Methodological Challenges
 
There are a number of unique characteristics of med-
ical devices and the treatment evaluation process that
affect clinical trial design and PRO evaluation. First,
double-blind, placebo-controlled trials can be difﬁcult
to perform for medical devices because of logistical
and ethical reasons. Randomization to a device versus
no device (or a sham procedure) may not be appropri-
ate when risks are high or beneﬁts are not clinically
disputed, such as the use of percutaneous coronary
intervention for symptomatic, obstructive atheroscle-
rotic disease. In such cases, active-control or single-
arm studies might be more practical to implement.
Because clinician investigators and patients may not be
blinded to treatment assignment in many device stud-
ies, there is a possibility of bias when measuring PROs.
Bias could take the form of subtle differences in the
approach investigators take with their patients, includ-
ing querying patients for clinical symptoms, as well as
the patient’s perception of treatment and treatment
effects. Thus, study design should include carefully
constructed methods for minimizing and/or describing
this bias, including careful respondent training, inde-
pendent observation or evaluation, statistical control
variables, such as social desirability indicators, and
sensitivity analyses.
The inherent complexity and invasiveness of certain
medical devices is an important contributing factor to
potentially small sample sizes characteristic of device
trials [12]. This can create a challenge achieving sta-
tistical signiﬁcance, even in the presence of large treat-
ment effects. Studies involving PROs must therefore be
carefully designed, with precise measurement, power
estimates, and a realistic 
 
a priori
 
 probability estimate.
It should be emphasized that, although large sample
sizes for PROs may not be feasible in device evalua-
tion, small, well-designed PRO studies can provide an
important building block to understand the impact of
treatment from the patient’s perspective.
The validity of any study, particularly those involv-
ing relatively small sample sizes, can be adversely
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affected by differential dropout rates, because of var-
iability in mortality or morbidity rates between treat-
ment arms. There are a number of situations, for
example, in which patients in one treatment arm are
too moribund to complete follow-up assessment tools,
leading to under-reporting of negative patient-reported
data and the erroneous conclusion that health-related
quality of life, or other similar outcome, was not
adversely affected by treatment. In fact, this problem is
not unique to device studies, with examples in the
literature regarding study design and statistical
approaches to address this problem in drug trials,
based on extensive experience with this problem in
oncology studies [13].
Table 1 lists major potential confounding factors
that should be addressed in device evaluations. A chal-
lenge which is most unique to devices is differentiating
the impact of the procedure, in the hands of the phy-
sician, from the technology itself. Studies with “run-
in” phases allow investigators to gain experience with
the product and can reduce variability in both medical
efﬁcacy and PROs. Evaluation of this cohort is often
performed separately from the randomized phase of
the trial to evaluate and control for the “learning
curve” effect.
Another important difference between device and
drug therapies is the speed of technological advances
and the duration of product life cycles. The average
product life cycle of devices is considerably shorter
than that of drugs: time-to-obsolescence of medical
devices is typically measured in months, contrasted
with small molecule therapeutics, which usually have
product life cycles of several years. Device manufac-
tures must keep pace with the rapidly changing tech-
nological environment through incremental product
improvements—making long-term preapproval studies
of the ﬁnal design difﬁcult to conduct [12]. Shorter-
term studies are more ideal, evaluating the immediate
post-treatment outcomes in light of regulatory require-
ments for approval. PROs may include short-term
activities of daily living, return to work, or satisfac-
tion. Evaluating the effects of treatment on long-term
patient outcomes, such as physical or social function,
caregiver burden, or health-related quality of life could
be performed during longitudinal postapproval trials
or registries.
The methodological challenges in device studies
also highlight the need for consensus on the best (valid,
reliable, sensitive) PRO assessment tools for speciﬁc
therapeutic areas, such as heart failure trials. These
measures should be sensitive enough to capture the
health effects attributable to the device, but generic
enough to apply to outcomes across treatment options,
for example, device versus device or device versus
drug. Using the same measures across studies would
facilitate cross-study comparisons and meta-analysis
and contribute to evidence-based decision-making.
 
Case Examples: PROs in Heart Failure and Shunt 
Device Evaluation
 
In many respects, one of the most inﬂuential cardio-
vascular clinical studies to date involving PRO meas-
ures was the Randomized Evaluation of Mechanical
Assistance for the Treatment of Congestive Heart Fail-
ure (REMATCH) study, which evaluated the use of left
ventricular assist device (LVAD) therapy as destination
therapy for end-stage heart failure patients ineligible
for cardiac transplant [14]. The REMATCH study
assigned patients to either receive the HeartMate
(Thoratec Corporation, Pleasanton, CA) LVAD or
receive optimal medical management. A total of 129
patients were enrolled into the study, with the primary
end point of the study being all-cause mortality. As a
secondary end point, health-related quality-of-life
measures were evaluated in a subset of patients,
including general and speciﬁc instruments such as the
36-Item Short-Form Health Survey and the Minnesota
Living with Heart Failure questionnaires. At the con-
clusion of the study, the results demonstrated a signif-
icant 1-year and 2-year reduction in mortality with the
device compared with optimal medical therapy (48%
vs. 75% at 1 year and 77% vs. 92% at 2 years for the
LVAD and medical therapy, respectively). Neverthe-
less, the rate of serious adverse events, including device
malfunction, infection, and bleeding, was signiﬁcantly
higher in the device arm (relative risk 2.35; 95% CI
1.86, 2.95).
While the REMATCH study demonstrated a
conclusive beneﬁt of LVAD therapy in terms of an
improvement in survival, the types and rates of serious
adverse events raised troubling questions. From a reg-
ulatory perspective, determination of device safety and
effectiveness was a very complex undertaking, because
of the need to determine the appropriate trade-off
between mortality beneﬁt and adverse events, as well
as to assess whether the survival beneﬁt demonstrated
with the LVAD was clinically meaningful. From the
clinical perspective, adoption of LVADs as destination
 
Table 1
 
Common differences in the impact of confounding
factors for medical device versus drug evaluations
 
Confounding factors
Product 
Device Drug
Inﬂuence of physician
technique on result
Higher Low/
Not relevant
Effect of accessories and
environment on
performance
(monitoring resources)
Higher Low/
Not relevant
Relationship between
procedure efﬁcacy
and treatment efﬁcacy
Higher Low/
Not relevant
Patient characteristics High High
Patient adherence High for nonimplanted 
devices/Not relevant
for implanted devices
High
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therapy for end-stage heart failure patients was not a
forgone conclusion. Given the complexities in inter-
preting the study data and the need to translate the
postulated treatment efﬁcacy based on individual
patient values and perceptions, the device performance
proﬁle might be acceptable to one patient yet unac-
ceptable to others. For both regulatory and clinical
purposes, having a reliable set of PRO measures would
have been very useful to assess product attributes.
Nevertheless, questions regarding generalizability of
the health-related quality-of-life substudy ﬁndings
because of the small response rate (27%) as well as
bias and confounding from differential rates of follow-
up limited the contribution of the quality-of-life data
in overall product assessment.
It is important to identify the reasons why patients
in a study sample may be unable to complete the PRO
measures in the study, especially if the study is limited
to a single arm without a comparator group. In a study
evaluating the application of a low-pressure shunt for
treatment of hydrocephalus, study patients/caregivers
were asked to complete a health-related quality-of-life
questionnaire that included questions comparing pre-
versus postoperative functional status [15]. Investigat-
ing the reasons why some patients had to be excluded
from the PRO evaluation addressed questions of pos-
sible nonresponse bias.
 
Alternative Approaches for Including PROs in 
Device Evaluation
 
For devices that improve survival, it is valuable to
demonstrate whether or not the respective survival
beneﬁt is clinically meaningful. A health utility instru-
ment, one type of PRO measure that integrates both
morbidity and mortality into a single parameter, may
be quite useful in the evaluation of such devices. Utility
weights reﬂect a person’s preferences for different
health states and can be combined with life expectancy
to compute quality-adjusted life-years for two treat-
ments being compared.
In addition to health utility measures, types of
PROs that increasingly have been used with success in
device evaluations include treatment preference and
satisfaction measures. For example, patient satisfac-
tion was captured in a clinical trial for the SOUND-
TEC device, a semi-implantable hearing system, which
found that overall subject satisfaction improved 17%
over  previously  worn  hearing  aids  [16].  Measures
of patient satisfaction have been incorporated into a
wide range of device studies, including studies of an
Internet-based telehealth system [17] and maxillary
obturator [18]. In addition, satisfaction and treatment
preference measures in a two-way crossover study
comparing  a  linear  analog  versus  a  digital  hearing
aid showed signiﬁcant differences favoring the digital
hearing aid [19]. Incorporating satisfaction and/or
preference measures into such studies enables one to
assess whether or not efﬁcacy translates into satisfac-
tion and to identify the speciﬁc technology-related fac-
tors that contribute to higher satisfaction or greater
preferences. In some device studies, such as the digital
hearing aid study [19], preference scales may be the
most sensitive measures relative to other patient-
reported scales in distinguishing between alternative
devices, providing more thorough insight into deci-
sion-making in the study population. It should be
noted that satisfaction scale scores are typically
skewed upward, reducing their ability to differentiate
among comparators. Assessment of treatment prefer-
ences in these situations is more informative.
In addition to expanding beyond traditional health-
related quality-of-life measures for implementing
PROs in device studies, alternative study designs to
randomized controlled trials may be useful in device
evaluation. Single-arm studies, in which patients serve
as their own controls, may be appropriate. A recent
study of the quality-of-life effects of ICD used a single-
group pre–post  study  design,  which  involved  one
arm with both pre- and postintervention assessments.
Because a standardized general quality-of-life measure,
the 36-Item Short-Form Health Survey, was used, the
results of the study could be compared with published
data serving as group-level age- and sex-matched nor-
mative controls, or with published data from a group
of patients referred to tertiary care centers for atrial
ﬁbrillation management [20]. In another pre–post
device study of the distal urethral polypropylene sling
for incontinence, patients were stratiﬁed at baseline
based on severity of condition, and all patients
improved in health-related quality of life regardless of
baseline severity levels [21]. To address the small sam-
ple sizes in some device studies, researchers also have
performed meta-analyses of published trials to evalu-
ate PROs and implemented registries to track out-
comes in large populations [22]. Although multicenter
studies could ease some study design concerns related
to randomization, blinding, and sample size, these
studies pose additional issues such as interoperator
variability in device evaluations and may produce
biases associated with differences in physician tech-
nique. Study center experience and procedural volume
is an important confounder for some device trials
(Table 1).
Registries are also useful when randomization
proves not to be feasible. An example is the evaluation
of uterine ﬁbroid embolization (UFE). UFE is a mini-
mally invasive approach for managing painful noncan-
cerous uterine ﬁbroids, offering women an alternative
to surgery (e.g., hysterectomy). Understanding the
patient’s perspective of UFE would provide valuable
insights into its value as a treatment alternative. A ran-
domized design was used to evaluate PROs of treat-
ment. Nevertheless, recruitment of women into the
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trial was extremely difﬁcult. Those invited to enroll in
the study preferred to choose the less invasive treat-
ment, rather than risk the chance of being randomized
to the surgical group. The effort was abandoned in
favor of a registry under the direction of Dr G. Pron,
now underway, in which the patient’s perspective and
satisfaction with treatment is examined along with
medical outcomes of therapy [23].
 
Standards of Evidence: Uniform Requirements 
for PROs in Device Evaluation
 
Signiﬁcant attention is being given to the role PROs
play in the drug development process and the stand-
ards of evidence required for PRO data to be included
in labeling and promotional claims [24–26]. The intent
is to make certain that the patient’s perspective is com-
municated accurately and fairly to the key stakehold-
ers: to patients, as informed consumers; to providers,
including clinicians delivering care and caregivers as
participants in the health-care process; and to payers,
as buyers of health-care services.
There is general consensus across industry, the clin-
ical community, and regulatory authorities that PRO
data must: 1) reﬂect the perspective of the patient; 2)
be  accurate  and  unbiased,  with  rigorous  adherence
to scientiﬁc measurement, design, analyses; and 3) be
communicated appropriately and effectively, with full
disclosure and unbiased reporting. More speciﬁcally,
the selected outcome should be signiﬁcant to the
patient and appropriate to the treatment effect; the
measurement instrument must be psychometrically
sound—that is to say—precise, reproducible, valid,
and interpretable; the study design must be appropri-
ate to the hypothesis, with appropriate measurement
intervals and methods for data capture; and the statis-
tical analyses must be carefully planned and imple-
mented [24,25].
These same general principles of scientiﬁc quality
can, and should, be applied to the medical device
industry—that is, to the use of PROs in understanding
the effects of intervention with new medical technolo-
gies. Translating these general principles to the unique
characteristics of the device industry in general, and
the technological diversity in particular, presents new
and important challenges at all levels—practical, meth-
odological, and regulatory. Given the complexities and
unique challenges involved in device evaluation, a
“one size ﬁts all” approach would be ill-advised. At
the same time, attention should always be given to
scientiﬁc quality and rigor.
 
Discussion
 
The value of patient-reported information for under-
standing the patients’ perspective of treatment is
equally important for device therapies as for drug ther-
apies. Researchers are faced with unique challenges
associated with device trials, as discussed in this arti-
cle. Given the great diversity in the types of devices and
the speed with which innovations are introduced,
effective assessment of the patient’s perspective of new
health technologies requires collaboration of industry,
the clinical community, and regulatory agencies to
maximize efﬁciency and expedite not only the devel-
opment of new technologies [27,28], but their absolute
and relative value in improving health and enhancing
the quality and/or cost-effectiveness of health-care
delivery.
Data captured through PRO measures provide
important information on the beneﬁts of new technol-
ogies in an environment that historically emphasized
risks, hazards, and device failures, often negating ben-
eﬁt [28,29]. For example, in hearings before the Senate
Subcommittee on Public Health and Welfare in 1974,
testimony was given that more than 500 persons had
died because of the use of defective heart valves, but
little or no consideration was given to the fact that
more than 200,000 people were alive because the heart
valves had been used [23]. In addition, despite a rela-
tively large body of evidence conﬁrming automated
external deﬁbrillation as a major breakthrough for
improving survival after sudden cardiac death, public
conﬁdence in deﬁbrillators was diminished with wide-
spread attention given to reports of malfunction
associated with a device produced by one of the man-
ufacturers [29].
Innovations in medical technology have greatly
enhanced prevention-oriented and therapeutic options
in health care, often achieving PRO beneﬁts long
before a morbidity or mortality end point is realized. A
wider array of technologies is being required to
undergo more rigorous clinical evaluations before reg-
ulatory approval. To fully capture the risks and bene-
ﬁts of treatment, device evaluation should incorporate
all aspects of the device’s function, safety, and effec-
tiveness, including the patient’s experience and per-
spective. Devices speciﬁcally designed to be life-saving
or life-supporting should be assessed to assure that
they also are maintaining or improving patient health-
related quality of life to inform decision-making at the
patient, provider, and reimbursement levels.
The FDA’s mandate is to consider valid scientiﬁc
evidence to support regulatory submissions for
approval, and to consider the least burdensome means
to demonstrate safety and effectiveness. The challenges
associated with PRO application have created con-
comitant challenges within the Agency, in light of this
mandate. These challenges also apply to postmarket
surveillance studies, which are increasingly becoming a
requirement for medical devices. Because the patient’s
perspective is an essential component of understanding
treatment effects, solutions to these challenges must
be found. Successful methodologies that have been
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applied to PROs in device evaluation include selecting
outcomes beyond traditional health-related quality of
life, such as patient preference and satisfaction, and
using alternatives to randomized controlled study
designs that are appropriate to the task, such as single-
arm pre–post studies, observational studies, multi-
center studies, and registries.
 
Conclusion
 
Medical device manufacturers, scientiﬁc and regula-
tory communities face important challenges as they
consider how to understand the impact of new medical
technologies from the perspective of the patients them-
selves. Similar to the application of PROs in drug
research, PROs can play an important role in the deci-
sion-making process for devices. The challenges facing
the medical device industry in gathering this empiric
evidence and communicating this important informa-
tion to health-care decision-makers are clear. With
additional work and open dialogue, however, these
challenges are not insurmountable.
 
This article represents the professional opinion of the authors
and is not an ofﬁcial document, agency guidance or policy of
the US Government, the Department of Health and Human
Services, or the Food and Drug Administration, nor should
any ofﬁcial endorsement be inferred.
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